• Executive Summary o Market Overview • Market Landscape o Market ecosystem o Value chain analysis • Market Sizing o Market definition o Market segment analysis o Market size 2019 o Market outlook: Forecast for 2019 - 2024 • Five Forces Analysis o Five forces summary o Bargaining power of buyers o Bargaining power of suppliers o Threat of new entrants o Threat of substitutes o Threat of rivalry o Market condition • Market Segmentation by Application o Market segments o Comparison by Application o Gastrointestinal disorders - Market size and forecast 2019-2024 o Immunological conditions - Market size and forecast 2019-2024 o Others - Market size and forecast 2019-2024 o Market opportunity by application • Customer landscape • Geographic Landscape o Geographic segmentation o Geographic comparison o North America - Market size and forecast 2019-2024 o Europe - Market size and forecast 2019-2024 o APAC - Market size and forecast 2019-2024 o ROW - Market size and forecast 2019-2024 o Key leading countries o Market opportunity by geography o Market drivers o Market challenges o Market trends • Vendor Landscape o Vendor landscape o Landscape disruption • Vendor Analysis o Vendors covered o Market positioning of vendors o Bristol-Myers Squibb Co. o Dow Inc. o ENTEROME SA o Ferring Pharmaceuticals AS o Johnson & Johnson o Kaleido Biosciences Inc. o PureTech Health Plc o Second Genome Therapeutics o Seres Therapeutics Inc. o Takeda Pharmaceutical Co. Ltd. • Appendix o Scope of the report o Currency conversion rates for US$ o Research methodology o List of abbreviations Exhibit • 1: Key Finding 1 • 2: Key Finding 2 • 3: Key Finding 3 • 4: Key Finding 5 • 5: Key Finding 6 • 6: Key Finding 7 • 7: Key Finding 8 • 8: Parent market • 9: Market characteristics • 10: Offerings of vendors included in the market definition • 11: Market segments • 12: Global - Market size and forecast 2019 - 2024 ($ million) • 13: Global market: Year-over-year growth 2019 - 2024 (%) • 14: Five forces analysis 2019 & 2024 • 15: Bargaining power of buyers • 16: Bargaining power of suppliers • 17: Threat of new entrants • 18: Threat of substitutes • 19: Threat of rivalry • 20: Market condition - Five forces 2019 • 21: Application - Market share 2019-2024 (%) • 22: Comparison by Application • 23: Gastrointestinal disorders - Market size and forecast 2019-2024 ($ million) • 24: Gastrointestinal disorders - Year-over-year growth 2019-2024 (%) • 25: Immunological conditions - Market size and forecast 2019-2024 ($ million) • 26: Immunological conditions - Year-over-year growth 2019-2024 (%) • 27: Others - Market size and forecast 2019-2024 ($ million) • 28: Others - Year-over-year growth 2019-2024 (%) • 29: Market opportunity by Application • 30: Customer landscape • 31: Market share by geography 2019-2024 (%) • 32: Geographic comparison • 33: North America - Market size and forecast 2019-2024 ($ million) • 34: North America - Year-over-year growth 2019-2024 (%) • 35: Europe - Market size and forecast 2019-2024 ($ million) • 36: Europe - Year-over-year growth 2019-2024 (%) • 37: APAC - Market size and forecast 2019-2024 ($ million) • 38: APAC - Year-over-year growth 2019-2024 (%) • 39: ROW - Market size and forecast 2019-2024 ($ million) • 40: ROW - Year-over-year growth 2019-2024 (%) • 41: Key leading countries • 42: Market opportunity by geography ($ million) • 43: Impact of drivers and challenges • 44: Vendor landscape • 45: Landscape disruption • 46: Industry risks • 47: Vendors covered • 48: Market positioning of vendors • 49: Bristol-Myers Squibb Co. - Overview • 50: Bristol-Myers Squibb Co. - Business segments • 51: Bristol-Myers Squibb Co. - Key offerings • 52: Bristol-Myers Squibb Co. - Key customers • 53: Bristol-Myers Squibb Co. - Segment focus • 54: Dow Inc. - Overview • 55: Dow Inc. - Business segments • 56: Dow Inc. - Key offerings • 57: Dow Inc. - Key customers • 58: Dow Inc. - Segment focus • 59: ENTEROME SA - Overview • 60: ENTEROME SA - Product and service • 61: ENTEROME SA - Key offerings • 62: ENTEROME SA - Key customers • 63: ENTEROME SA - Segment focus • 64: Ferring Pharmaceuticals AS - Overview • 65: Ferring Pharmaceuticals AS - Product and service • 66: Ferring Pharmaceuticals AS - Key offerings • 67: Ferring Pharmaceuticals AS - Key customers • 68: Ferring Pharmaceuticals AS - Segment focus • 69: Johnson & Johnson - Overview • 70: Johnson & Johnson - Business segments • 71: Johnson & Johnson - Key offerings • 72: Johnson & Johnson - Key customers • 73: Johnson & Johnson - Segment focus • 74: Kaleido Biosciences Inc. - Overview • 75: Kaleido Biosciences Inc. - Product and service • 76: Kaleido Biosciences Inc. - Key offerings • 77: Kaleido Biosciences Inc. - Key customers • 78: Kaleido Biosciences Inc. - Segment focus • 79: PureTech Health Plc - Overview • 80: PureTech Health Plc - Business segments • 81: PureTech Health Plc - Key offerings • 82: PureTech Health Plc - Key customers • 83: PureTech Health Plc - Segment focus • 84: Second Genome Therapeutics - Overview • 85: Second Genome Therapeutics - Product and service • 86: Second Genome Therapeutics - Key offerings • 87: Second Genome Therapeutics - Key customers • 88: Second Genome Therapeutics - Segment focus • 89: Seres Therapeutics Inc. - Overview • 90: Seres Therapeutics Inc. - Product and service • 91: Seres Therapeutics Inc. - Key offerings • 92: Seres Therapeutics Inc. - Key customers • 93: Seres Therapeutics Inc. - Segment focus • 94: Takeda Pharmaceutical Co. Ltd. - Overview • 95: Takeda Pharmaceutical Co. Ltd. - Product and service • 96: Takeda Pharmaceutical Co. Ltd. - Key offerings • 97: Takeda Pharmaceutical Co. Ltd. - Key customers • 98: Takeda Pharmaceutical Co. Ltd. - Segment focus • 99: Currency conversion rates for US$ • 100: Research Methodology • 101: Validation techniques employed for market sizing • 102: Information sources • 103: List of abbreviations

Bristol-Myers Squibb Co., Dow Inc., ENTEROME SA, Ferring Pharmaceuticals AS, Johnson & Johnson, Kaleido Biosciences Inc., PureTech Health Plc, Second Genome Therapeutics, Seres Therapeutics Inc., Takeda Pharmaceutical Co. Ltd.